Symptomatic reflux disease: the present, the past and the future
The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epi...
Gespeichert in:
Veröffentlicht in: | Gut 2014-07, Vol.63 (7), p.1185-1193 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1193 |
---|---|
container_issue | 7 |
container_start_page | 1185 |
container_title | Gut |
container_volume | 63 |
creator | Boeckxstaens, Guy El-Serag, Hashem B Smout, André J P M Kahrilas, Peter J |
description | The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future. |
doi_str_mv | 10.1136/gutjnl-2013-306393 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4078752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1534468604</sourcerecordid><originalsourceid>FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</originalsourceid><addsrcrecordid>eNqNkUuP0zAUhS0EYkrhD7BAkdiwmMC98TMsEKOKl1SJBbC2HMfupMqj2M6I-ffjkqECVl1ZV_7u0bnnEPIc4TUiFW92c9qPfVkB0pKCoDV9QFbIhCpppdRDsgJAWXLJ6gvyJMY9AChV42NyUTEBsqZiRd5_ux0OaRpM6mwRnO_nX0XbRWeie1uka1ccgotuTJfLYGIqzNj-Hvyc5uCekkfe9NE9u3_X5MfHD983n8vt109fNlfbsuFCprJWjCqGrRfSAmPIGEch2xq4deAlqzwHb5Xw3HInGRpf2cYiArZU8IbRNXm36B7mZnCtzZ6C6fUhdIMJt3oynf73Z-yu9W660QykkrzKAq_uBcL0c3Yx6aGL1vW9Gd00R42SUyYl0jPQTOaYBRxtvfwP3U9zGHMSWVDWjNeCHQWrhbJhijHHfPKNoI9d6qVLfexSL13mpRd_X3xa-VNeBsoFaIb9OYJ3R5io4A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779459642</pqid></control><display><type>article</type><title>Symptomatic reflux disease: the present, the past and the future</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Boeckxstaens, Guy ; El-Serag, Hashem B ; Smout, André J P M ; Kahrilas, Peter J</creator><creatorcontrib>Boeckxstaens, Guy ; El-Serag, Hashem B ; Smout, André J P M ; Kahrilas, Peter J</creatorcontrib><description>The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gutjnl-2013-306393</identifier><identifier>PMID: 24607936</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Acids ; Antacids - therapeutic use ; Combined Modality Therapy ; Disease Progression ; Endoscopy ; Epidemiology ; Gastroesophageal reflux ; Gastroesophageal Reflux - epidemiology ; Gastroesophageal Reflux - etiology ; Gastroesophageal Reflux - physiopathology ; Gastroesophageal Reflux - therapy ; Global Health ; Hernias ; Humans ; Laparoscopy ; Life Style ; Mortality ; Obesity ; Pathogenesis ; Proton Pump Inhibitors - therapeutic use ; Recent Advances in Clinical Practice ; Risk Factors ; Risk Reduction Behavior ; Studies ; Trends</subject><ispartof>Gut, 2014-07, Vol.63 (7), p.1185-1193</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2014 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</citedby><cites>FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://gut.bmj.com/content/63/7/1185.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttp://gut.bmj.com/content/63/7/1185.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>114,115,230,314,723,776,780,881,3183,23550,27901,27902,53766,53768,77342,77373</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24607936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boeckxstaens, Guy</creatorcontrib><creatorcontrib>El-Serag, Hashem B</creatorcontrib><creatorcontrib>Smout, André J P M</creatorcontrib><creatorcontrib>Kahrilas, Peter J</creatorcontrib><title>Symptomatic reflux disease: the present, the past and the future</title><title>Gut</title><addtitle>Gut</addtitle><description>The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.</description><subject>Acids</subject><subject>Antacids - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Disease Progression</subject><subject>Endoscopy</subject><subject>Epidemiology</subject><subject>Gastroesophageal reflux</subject><subject>Gastroesophageal Reflux - epidemiology</subject><subject>Gastroesophageal Reflux - etiology</subject><subject>Gastroesophageal Reflux - physiopathology</subject><subject>Gastroesophageal Reflux - therapy</subject><subject>Global Health</subject><subject>Hernias</subject><subject>Humans</subject><subject>Laparoscopy</subject><subject>Life Style</subject><subject>Mortality</subject><subject>Obesity</subject><subject>Pathogenesis</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Recent Advances in Clinical Practice</subject><subject>Risk Factors</subject><subject>Risk Reduction Behavior</subject><subject>Studies</subject><subject>Trends</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkUuP0zAUhS0EYkrhD7BAkdiwmMC98TMsEKOKl1SJBbC2HMfupMqj2M6I-ffjkqECVl1ZV_7u0bnnEPIc4TUiFW92c9qPfVkB0pKCoDV9QFbIhCpppdRDsgJAWXLJ6gvyJMY9AChV42NyUTEBsqZiRd5_ux0OaRpM6mwRnO_nX0XbRWeie1uka1ccgotuTJfLYGIqzNj-Hvyc5uCekkfe9NE9u3_X5MfHD983n8vt109fNlfbsuFCprJWjCqGrRfSAmPIGEch2xq4deAlqzwHb5Xw3HInGRpf2cYiArZU8IbRNXm36B7mZnCtzZ6C6fUhdIMJt3oynf73Z-yu9W660QykkrzKAq_uBcL0c3Yx6aGL1vW9Gd00R42SUyYl0jPQTOaYBRxtvfwP3U9zGHMSWVDWjNeCHQWrhbJhijHHfPKNoI9d6qVLfexSL13mpRd_X3xa-VNeBsoFaIb9OYJ3R5io4A</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Boeckxstaens, Guy</creator><creator>El-Serag, Hashem B</creator><creator>Smout, André J P M</creator><creator>Kahrilas, Peter J</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>Symptomatic reflux disease: the present, the past and the future</title><author>Boeckxstaens, Guy ; El-Serag, Hashem B ; Smout, André J P M ; Kahrilas, Peter J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acids</topic><topic>Antacids - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Disease Progression</topic><topic>Endoscopy</topic><topic>Epidemiology</topic><topic>Gastroesophageal reflux</topic><topic>Gastroesophageal Reflux - epidemiology</topic><topic>Gastroesophageal Reflux - etiology</topic><topic>Gastroesophageal Reflux - physiopathology</topic><topic>Gastroesophageal Reflux - therapy</topic><topic>Global Health</topic><topic>Hernias</topic><topic>Humans</topic><topic>Laparoscopy</topic><topic>Life Style</topic><topic>Mortality</topic><topic>Obesity</topic><topic>Pathogenesis</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Recent Advances in Clinical Practice</topic><topic>Risk Factors</topic><topic>Risk Reduction Behavior</topic><topic>Studies</topic><topic>Trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boeckxstaens, Guy</creatorcontrib><creatorcontrib>El-Serag, Hashem B</creatorcontrib><creatorcontrib>Smout, André J P M</creatorcontrib><creatorcontrib>Kahrilas, Peter J</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boeckxstaens, Guy</au><au>El-Serag, Hashem B</au><au>Smout, André J P M</au><au>Kahrilas, Peter J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Symptomatic reflux disease: the present, the past and the future</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>63</volume><issue>7</issue><spage>1185</spage><epage>1193</epage><pages>1185-1193</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><coden>GUTTAK</coden><abstract>The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>24607936</pmid><doi>10.1136/gutjnl-2013-306393</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0017-5749 |
ispartof | Gut, 2014-07, Vol.63 (7), p.1185-1193 |
issn | 0017-5749 1468-3288 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4078752 |
source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
subjects | Acids Antacids - therapeutic use Combined Modality Therapy Disease Progression Endoscopy Epidemiology Gastroesophageal reflux Gastroesophageal Reflux - epidemiology Gastroesophageal Reflux - etiology Gastroesophageal Reflux - physiopathology Gastroesophageal Reflux - therapy Global Health Hernias Humans Laparoscopy Life Style Mortality Obesity Pathogenesis Proton Pump Inhibitors - therapeutic use Recent Advances in Clinical Practice Risk Factors Risk Reduction Behavior Studies Trends |
title | Symptomatic reflux disease: the present, the past and the future |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T21%3A54%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Symptomatic%20reflux%20disease:%20the%20present,%20the%20past%20and%20the%20future&rft.jtitle=Gut&rft.au=Boeckxstaens,%20Guy&rft.date=2014-07-01&rft.volume=63&rft.issue=7&rft.spage=1185&rft.epage=1193&rft.pages=1185-1193&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gutjnl-2013-306393&rft_dat=%3Cproquest_pubme%3E1534468604%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779459642&rft_id=info:pmid/24607936&rfr_iscdi=true |